GNTI-823, an allogeneic engineered Treg product for the treatment of inflammatory and ischemic disease
GNTI-823 is an off-the-shelf, allogeneic engineered Treg (EngTregs™) product designed to rein in runaway inflammatory responses and mediate tissue repair in patients suffering from diverse acute inflammatory and ischemic diseases such as acute kidney injury, acute lung injury, and ischemic stroke. GNTI-823 is engineered to express a tissue Treg associated receptor, ST2, which drives a strong anti-inflammatory and pro-repair phenotype in response to alarmins released by damaged tissue. In this way, GNTI-823 exhibits an inflammation-specific rather than antigen-specific homing mechanism, allowing it to be applied across a broad range of inflammatory indications
About Acute Inflammatory and Ischemic Disease
Acute inflammatory and ischemic diseases represent a significant unmet medical need with no existing standard of care. In the US alone each year, over 3 million patients suffer from acute kidney injury, 800,000 from ischemic stroke, and 190,000 from acute respiratory distress syndrome. While diverse in etiology and organ site, these conditions are all associated with uncontrolled inflammation, tissue injury, and faulty repair processes that result in lasting damage. High morbidity and mortality are seen in the vast majority of cases and even patients who recover from the initial acute event often experience enduring and life-altering symptoms such as progression to chronic kidney disease, difficulties in speech and motor function in the case of stroke, and permanent lung dysfunction and cognitive impairment in the case of acute lung injury. An off-the-shelf therapy capable of both halting the runaway inflammatory response while promoting repair of damaged tissue could have a major impact on not only survival rates but on quality of life for millions of patients each year